In the study, treatment is given in a planned course over several cycles. Naxitamab is added to the usual early treatment, and patients are followed through the treatment period and into the next phase of care. The study also looks at side effects, including pain during the infusion, and other safety concerns. It will compare the results with older records from similar patients who received standard treatment without naxitamab.

Neuroblastoma is a cancer that starts in nerve cells, most often in young children. The study is focused on whether this added treatment can improve the early treatment outcome for patients with newly diagnosed high-risk disease.

The purpose of the study is to see whether using indocyanine green during surgery helps the team find and remove more lymph nodes (small glands that are part of the body’s immune system) and whether this changes the surgery in any helpful or harmful way. Some patients will have surgery with the dye and the special light imaging, while others will have the same type of surgery without it. The study includes operations such as nephroureterectomy (removal of a kidney and the tube that carries urine from it) and retroperitoneal lymph node dissection (removal of lymph nodes from the back part of the abdomen).

During the study, the dye is given before or during surgery, and the surgical team then carries out the planned operation and removes tissue as needed. After surgery, the medical team checks for any side effects from the dye and watches for usual surgery-related problems during recovery. The study also looks at how the surgery went overall and how well the dye appeared to help during the procedure.

The main goal of this research is to understand the long-term safety of GD2IL18CART treatment. The study will follow patients who have already received this treatment to monitor how they respond over time. During the study, doctors will track any delayed side effects that might occur, including the possibility of infections, cancer returning, or new health problems developing.

The study involves regular check-ups to monitor patients’ health status. For younger patients, growth and development will also be monitored. The research team will collect information about the patients’ overall health and perform tests to check if the treatment cells are still present in their bodies. This long-term monitoring will help understand how the treatment affects patients over time.

The study is designed as a platform trial with multiple treatment arms, meaning different treatment combinations will be tested simultaneously. Some medications will be given by mouth, while others will be administered through an intravenous line (directly into the vein). The treatments will be given in cycles, and patients will be monitored for up to 12 treatment cycles.

During the study, doctors will track how well the treatments work by measuring if the cancer stops growing or shrinks, how long patients live without their disease getting worse, and how long they survive overall. They will also monitor side effects and assess quality of life using questionnaires. Patients will have regular medical examinations, including scans and blood tests, to evaluate their response to treatment.

Participants in the study will receive the Anti-GD2-800CW treatment through an intravenous infusion, which means it will be given directly into a vein. The study will monitor how the treatment works in the body and how well it helps in identifying cancer cells during surgery. Researchers will also keep track of any side effects that might occur from the treatment. The study aims to ensure that the treatment is safe and that it helps surgeons to better distinguish between cancerous and healthy tissues during operations.

The trial will take place over several months, with participants undergoing regular check-ups and tests to monitor their health and the effectiveness of the treatment. Blood samples will be collected at different times to understand how the treatment is processed by the body. The study will also evaluate how visible the cancer is during surgery when using the Anti-GD2-800CW treatment, helping to improve surgical outcomes for children with neuroblastoma.

The purpose of the study is to evaluate the safety and effectiveness of the iC9-GD2-CAR T cells in treating these cancers. Participants will receive the treatment through an intravenous infusion, which means the medicine is given directly into a vein. The study is divided into two phases. In the first phase, the focus is on determining the safest dose of the T cells. In the second phase, the study will look at how well the treatment works at the best dose found in the first phase. The study will monitor how the T cells behave in the body, including how long they stay active and how well they reach and affect the tumors.

This trial is an important step in exploring new ways to treat difficult-to-treat cancers in young patients. By participating, researchers hope to gather valuable information that could lead to better treatments in the future. The study is expected to continue for several years to gather comprehensive data on the treatment’s safety and effectiveness.

After the transplant, patients will receive immunotherapy, which includes an infusion of donor-derived NK cells and an anti-cancer antibody known as anti-GD2 monoclonal antibody. These treatments are given to help the patient’s immune system fight the cancer more effectively. The study will monitor various outcomes, including overall survival, how well the donor cells take hold in the patient’s body, and any side effects related to the treatments.

The medications and treatments used in this study include Rituximab (also known by code names like CT-P10 and PF-05280586), Dinutuximab beta, Melphalan, Thiotepa, Fludarabine phosphate, and Anti-T lymphocyte immunoglobulin. These are administered as solutions for infusion, meaning they are given directly into the bloodstream through a vein. The study aims to provide valuable information on the potential benefits and risks of these treatments for patients with relapsed or resistant high-risk neuroblastoma.

The purpose of the study is to find out the highest dose of 177Lu-DOTATATE that can be given safely to children with neuroblastoma. During the study, children will receive the medication and be closely monitored to see how their bodies react to it. The study will also look at how safe the treatment is and how it affects the cancer. Another medication, LysaKare, which contains arginine hydrochloride and lysine hydrochloride, may also be used to help protect the kidneys during the treatment.

Participants in the study will receive the treatment over a period of time and will have regular check-ups to monitor their health and the effects of the treatment. The study aims to gather important information that could help improve treatment options for children with neuroblastoma in the future. A placebo may be used in some parts of the study to compare the effects of the treatment. The study is expected to continue until 2025.

The purpose of the study is to determine the best dose of LY3295668 Erbumine when used alone or in combination with other treatments, by assessing its safety and how well it is tolerated by patients. Participants in the study will receive the medication and be monitored for any side effects or changes in their condition. The study aims to see how the drug affects the tumors in patients with relapsed or refractory neuroblastoma, meaning the cancer has returned or is resistant to treatment.

Throughout the study, participants will be closely observed to ensure their safety, and researchers will collect data on how the drug impacts the cancer and the overall health of the participants. The study will help determine if LY3295668 Erbumine can be a viable treatment option for neuroblastoma in the future.

Participants in the study will receive one of the treatment combinations, and some may receive a placebo. The study will monitor the safety and effectiveness of these treatments over time. The trial will also look at how the body processes these medications and their impact on the participants’ quality of life. The study aims to find the best dose of these medications that can be safely given to patients.

The trial will involve regular check-ups and tests, such as MRI or CT scans, to track the progress of the treatment. Participants will be closely monitored for any side effects or changes in their condition. The study is expected to continue until November 2025, with the goal of improving treatment options for young patients with these challenging cancers.

The purpose of this study is to compare how well these two imaging methods can detect cancer in the bones of patients with neuroblastoma. Participants in the study will undergo both types of scans, and the results will be compared to see which method is more effective at finding cancerous lesions. The study will also look at other factors, such as the amount of radiation absorbed by the body during each type of scan and the number of cancerous areas detected.

This study is expected to take place over several years, with the goal of improving the way neuroblastoma is diagnosed and monitored. By comparing these two imaging methods, researchers hope to find the most accurate and safe way to detect this type of cancer, which could lead to better treatment outcomes for patients in the future.

The purpose of this study is to determine the best dose of ABTL0812 for children, both when used alone and when combined with other treatments. The study will involve several phases, starting with a small group of participants to find the safest and most effective dose. As the study progresses, more participants will be included to further evaluate the treatment’s effects. Participants will receive the study medication and be monitored by healthcare professionals to assess how well the treatment is working and to identify any side effects.

Throughout the study, participants will have regular check-ups and tests to monitor their health and the progress of their treatment. The study aims to provide valuable information that could lead to better treatment options for children with neuroblastoma and other solid tumors. Participants will be closely observed to ensure their safety and to gather data on how the treatment affects their condition.

The purpose of the study is to determine if these combinations can improve treatment outcomes for children whose neuroblastoma has returned or has not responded to previous treatments. Participants in the study will receive one of these treatment combinations, or a placebo, over a period of up to 24 months. The study will monitor the participants’ response to the treatment, including any changes in the size of the tumor and the overall health of the participants.

Throughout the study, the safety of the treatments will be closely monitored, and any side effects will be recorded. The study aims to provide valuable information on whether these treatment combinations can offer better outcomes for children with relapsed or refractory neuroblastoma, potentially leading to improved treatment options in the future.

The purpose of the study is to compare the effectiveness of different treatment regimens over a three-year period. The study is divided into three phases: induction, high-dose chemotherapy, and radiotherapy. In the induction phase, two different chemotherapy regimens are compared. In the high-dose chemotherapy phase, a single high-dose treatment with busulfan and melphalan is compared to a tandem high-dose treatment with thiotepa followed by busulfan and melphalan. The radiotherapy phase compares two different radiation doses to the tumor area. Additionally, for patients who do not respond well to initial chemotherapy, a combination of chemotherapy and immunotherapy is introduced.

Participants in the study will receive one of the treatment strategies and will be monitored over time to assess the effectiveness of the treatment. The study will help determine which treatment strategy offers the best chance of improving survival and reducing the risk of cancer returning. The trial is expected to continue until 2031, with ongoing assessments of patient outcomes and responses to the treatments being tested.

The purpose of this study is to find the best dose of Crizotinib when used with Temsirolimus and to assess the safety and initial effectiveness of Crizotinib on its own in treating these specific gene-positive tumors. Participants in the study will receive either Crizotinib alone or in combination with Temsirolimus, depending on their specific cancer type and genetic markers. The study will monitor how the body responds to the treatment and any side effects that may occur.

Throughout the study, participants will undergo regular check-ups and tests to track their progress and the impact of the treatment on their cancer. The study aims to gather important information that could help improve treatment options for children with these types of cancers in the future. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatment. The study is expected to continue until the end of 2029.

The purpose of the study is to determine the safety and appropriate dosage of GD2IL18CART and to see how well it works in treating these cancers. Participants will receive the treatment through an intravenous infusion, which means it will be delivered directly into the bloodstream. The study will monitor participants for any side effects and measure how the cancer responds to the treatment over time. Some participants may receive a placebo, which is a substance with no active treatment, to compare the effects of the new therapy.

Throughout the study, researchers will carefully observe the participants’ health and the behavior of the cancer. The study aims to find the best dose of GD2IL18CART that is both safe and effective. Participants will be followed for a period to assess the treatment’s impact on their cancer and overall health. This trial is an important step in developing new therapies for cancers that are difficult to treat with existing methods.

The purpose of the study is to assess the safety and effectiveness of this combination of drugs. The study is divided into two phases. In the first phase, researchers will determine the best dose of ribociclib to use with the other medications. In the second phase, the study will further evaluate how well this combination works in treating neuroblastoma compared to a placebo. Participants will receive the medications either orally or through intravenous infusion, depending on the specific drug.

Throughout the study, participants will be closely monitored for any side effects and to see how their tumors respond to the treatment. The study aims to find the most effective and safe way to use these medications together to help treat these challenging cancers in young patients. The trial is expected to continue until 2029, allowing researchers to gather comprehensive data on the treatment’s impact.

The purpose of the study is to evaluate the safety of this combined treatment in patients whose neuroblastoma has either returned after treatment, continued to grow despite treatment, or did not respond to initial treatments. The study will involve 20 patients who will receive the combination of dinutuximab beta and chemotherapy. Their results will be compared to historical data from two groups of patients: one group that received only chemotherapy and another that received only immunotherapy.

Participants in the study will receive the treatment over a period of time, and researchers will monitor them for any side effects or reactions. The study aims to understand how safe and effective the combination of dinutuximab beta and chemotherapy is for treating neuroblastoma that is resistant to standard treatments. This research could provide valuable insights into new ways to manage this challenging disease.

The purpose of the study is to find out how safe and tolerable the combination of dinutuximab beta and chemotherapy is for patients, and to determine the best dose to use. Patients in the study will receive the treatment in cycles, which means they will have periods of receiving the medication followed by periods of rest. The study will monitor patients for any side effects and how their cancer responds to the treatment. Some patients may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatment.

The study will take place over several years, with patients being closely monitored throughout the process. The goal is to gather information on the safety and effectiveness of the treatment combination, which could lead to better treatment options for children with high-risk neuroblastoma in the future. Participants will be required to attend regular follow-up appointments to track their progress and any changes in their condition.

Participants in the study will receive the treatment in cycles, and the study will monitor the effects of the treatment over time. The study aims to find out how well the treatment works and to identify any side effects that may occur. The trial will help researchers understand the safest and most effective way to use ABTL0812 in treating these types of cancers in children.

The study is expected to continue for several years, with an estimated end date in 2028. During this time, researchers will gather information to help improve treatment options for children with relapsed or refractory neuroblastoma and other solid tumors. This research is important for developing new therapies that can offer better outcomes for young patients facing these challenging conditions.

Participants in the study will receive the 177Lutetium-DOTATATE treatment, and their response to the medication will be monitored over time. The study will also involve the use of imaging techniques, such as PET/CT scans, to observe changes in the cancer. These scans help doctors see how the treatment is affecting the cancer cells. The study will take place over several months, with regular check-ups to monitor the health and progress of the participants.

In addition to the main treatment, some participants may receive other supportive medications, such as LysaKare, which contains substances like L-lysine hydrochloride and L-arginine hydrochloride. These are used to help protect the kidneys during the treatment. The study aims to gather information on the effectiveness and safety of the treatment, as well as its impact on the participants’ overall health and survival. Participants will be closely monitored for any side effects or changes in their condition throughout the study period.

Participants in the study will receive the 68Ga-SATO treatment through an injection. The study will also involve comparing the effectiveness of 68Ga-SATO imaging with current standard imaging methods, such as M123IBG scintigraphy and, if available, whole-body MRI. This comparison aims to determine how well the new treatment can detect cancer lesions compared to existing methods.

Throughout the study, researchers will monitor the safety of the treatment and gather information on how the body absorbs the radiation from 68Ga-SATO. The study will also evaluate the time required for preparing and conducting the imaging procedure. The trial is expected to continue until December 2025, providing valuable insights into the potential benefits and safety of 68Ga-SATO for children with neuroblastoma.

The purpose of the study is to find out which combination of these treatments is safe and effective for young patients with these challenging types of cancer. In the first stage of the study, researchers will determine which of the three chemotherapy regimens is safe to use with Nivolumab. The regimens being tested are: Cyclophosphamide and Vinblastine; Capecitabine alone; and a combination of Cyclophosphamide, Vinblastine, and Capecitabine. In the second stage, the study will focus on the most promising regimen from the first stage, with or without Nivolumab, to see how well it works in preventing the cancer from getting worse.

Participants in the study will receive their treatments either through an intravenous method, which means the medication is given directly into a vein, or orally, which means taking the medication by mouth. The study will monitor the participants over time to assess the safety of the treatments and their effectiveness in controlling the cancer. The study aims to provide valuable information that could lead to better treatment options for children and teenagers facing these difficult cancers.

The purpose of the study is to determine the best treatment approach for patients by assessing their risk through gene expression analysis. This means that the study will look at how genes are expressed in the cancer cells to decide on the most suitable treatment plan. The trial will involve different groups of patients who will receive either intensified or reduced treatment based on their risk level. The study will monitor the patients over time to see how well they respond to the treatment and to check for any side effects.

Throughout the study, researchers will track the time from diagnosis to any significant events, such as the cancer returning or worsening. They will also look at overall survival rates and other factors that might affect the outcomes, like the age at diagnosis and specific genetic changes in the cancer cells. The trial will compare the results with historical data to understand the effectiveness of the treatments and the impact of any side effects. This research is expected to continue until 2035, with patient recruitment starting in 2024.